Jones RB - Search Results

1

Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease.

Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, Jayne DR. Roberts DM, et al. Among authors: jones rb. J Autoimmun. 2015 Feb;57:60-5. doi: 10.1016/j.jaut.2014.11.009. Epub 2014 Dec 31. J Autoimmun. 2015. PMID: 25556904

2

Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?

Flossmann O, Jones RB, Jayne DR, Luqmani RA. Flossmann O, et al. Among authors: jones rb. Ann Rheum Dis. 2006 Jul;65(7):841-4. doi: 10.1136/ard.2005.048900. Ann Rheum Dis. 2006. PMID: 16769779 Free PMC article. Review.

3

Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.

Smith KG, Jones RB, Burns SM, Jayne DR. Smith KG, et al. Among authors: jones rb. Arthritis Rheum. 2006 Sep;54(9):2970-82. doi: 10.1002/art.22046. Arthritis Rheum. 2006. PMID: 16947528 Free article. Clinical Trial.

4

Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production.

Pepper RJ, Fabre MA, Pavesio C, Gaskin G, Jones RB, Jayne D, Pusey CD, Salama AD. Pepper RJ, et al. Among authors: jones rb. Rheumatology (Oxford). 2008 Jul;47(7):1104-5. doi: 10.1093/rheumatology/ken175. Epub 2008 May 20. Rheumatology (Oxford). 2008. PMID: 18492710 No abstract available.

5

A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.

Jones RB, Ferraro AJ, Chaudhry AN, Brogan P, Salama AD, Smith KG, Savage CO, Jayne DR. Jones RB, et al. Arthritis Rheum. 2009 Jul;60(7):2156-68. doi: 10.1002/art.24637. Arthritis Rheum. 2009. PMID: 19565480 Free article.

6

B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study.

Martinez Del Pero M, Chaudhry A, Jones RB, Sivasothy P, Jani P, Jayne D. Martinez Del Pero M, et al. Among authors: jones rb. Clin Otolaryngol. 2009 Aug;34(4):328-35. doi: 10.1111/j.1749-4486.2009.01968.x. Clin Otolaryngol. 2009. PMID: 19673980

7

Treatment of primary systemic vasculitis with the inosine monophosphate dehydrogenase inhibitor mycophenolic acid.

Hiemstra TF, Jones RB, Jayne DR. Hiemstra TF, et al. Among authors: jones rb. Nephron Clin Pract. 2010;116(1):c1-10. doi: 10.1159/000314543. Epub 2010 May 12. Nephron Clin Pract. 2010. PMID: 20484933 Free article. Review.

8

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR; European Vasculitis Study Group. Jones RB, et al. N Engl J Med. 2010 Jul 15;363(3):211-20. doi: 10.1056/NEJMoa0909169. N Engl J Med. 2010. PMID: 20647198 Free article. Clinical Trial.

9

Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy.

Berden AE, Jones RB, Erasmus DD, Walsh M, Noël LH, Ferrario F, Waldherr R, Bruijn JA, Jayne DR, Bajema IM; European Vasculitis Society. Berden AE, et al. Among authors: jones rb. J Am Soc Nephrol. 2012 Feb;23(2):313-21. doi: 10.1681/ASN.2011040330. Epub 2011 Nov 17. J Am Soc Nephrol. 2012. PMID: 22095945 Clinical Trial.

10

Progress in treatment of ANCA-associated vasculitis.

Smith RM, Jones RB, Jayne DR. Smith RM, et al. Among authors: jones rb. Arthritis Res Ther. 2012 Apr 30;14(2):210. doi: 10.1186/ar3797. Arthritis Res Ther. 2012. PMID: 22569190 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

864 results

Search Page